Influenza, Human  >>  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
NCT01090453 / 2009-016635-36: Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Completed
2
480
Canada, Europe
GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™, Menjugate®, Rotarix™
GlaxoSmithKline
Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis, Acellular Pertussis, Diphtheria, Neisseria Meningitidis
10/11
10/11
NCT01248884 / 2010-021569-58: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Completed
2
721
Europe, RoW
Infanrix hexa™, DTPa-HBV-IPV/Hib, Prevenar 13®, Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine, GSK217744
GlaxoSmithKline
Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria
01/12
01/12

Download Options